Results for was evaluated translation from English to Swedish

this refocusing was evaluated positively.
dessa ändringar bedömdes som positiva.

efficacy was evaluated using panss.
effekt utvärderades med panss.

efficacy was evaluated using the panss.
effekten utvärderades med hjälp av panss.

efficacy was evaluated in 2,928 patients.
effekten utvärderades hos 2 928 patienter.

treatment effect was evaluated up to 29 days.
behandlingseffekten utvärderades upp till 29 dagar.

directive 76/211/eec was evaluated in 2005.
direktiv 76/211/eeg utvärderades 2005.

embryofoetal toxicity was evaluated in rats and rabbits.
embryofoetal toxicitet har utvärderats hos råtta och kanin.

maintenance of clinical remission was evaluated in charm.
bibehållande av klinisk remission utvärderades i charm.

eye swelling was evaluated in a review of 30 cases.
Ögonsvullnad utvärderades i en granskning av 30 fall.

the potential carcinogenicity of azacitidine was evaluated in mice and rats.
azacitidins potentiella karcinogenicitet utvärderades hos mus och råtta.

safety and tolerability was evaluated in the entire study population.
säkerhet och tolerabilitet utvärderades i hela studiepopulationen.

immunogenicity was evaluated in infants, children, adolescents and adults.
immunogeniciteten utvärderades hos spädbarn, barn, ungdomar och vuxna.

the safety profile of aprepitant was evaluated in approximately 4900 individuals.
säkerhetsprofilen för aprepitant utvärderades hos ca 4900 individer.

the incidence of new vertebral fractures was evaluated as a safety variable.
incidensen nya kotfrakturer utvärderades som säkerhetsvariabel.

the efficiency of the programme was evaluated according to the following questions:
programmets effektivitet utvärderades mot bakgrund av följande frågor:

twelve-month persistent infection was evaluated as additional efficacy endpoint.
tolv månaders persisterande infektion utvärderades som en ytterligare endpoint.

maintenance of clinical remission was evaluated in cd study iii (charm).
bibehållande av klinisk remission utvärderades i cd-studie iii (charm).

16 inhibitor development the immunogenicity of advate was evaluated in previously treated patients.
utveckling av inhibitorer advates immunogenicitet utvärderades hos tidigare behandlade patienter.

the financial management of projects was evaluated through the assessment of their financial reports.
den ekonomiska förvaltningen av projekten utvärderades genom granskning av de ekonomiska redovisningsrapporterna.

complete haematological response (chr) in cp patients was evaluated as a secondary endpoint.
fullständigt hematologiskt svar (chr) hos patienterna i kronisk fas bedömdes som ett sekundärt effektmått.